Open AccessThe Cost-effectiveness, Health Benefits, and Financial Costs of New Antiviral Treatments for Hepatitis C Virus
Author(s) -
David B. Rein,
John S. Wittenborn,
Bryce D. Smith,
Danielle K. Liffmann,
John W. Ward
Publication year - 2015
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/civ220
Subject(s) - medicine , sofosbuvir , ribavirin , cost effectiveness , simeprevir , quality adjusted life year , regimen , population , hepatitis c , hepatitis c virus , pegylated interferon , virology , environmental health , virus , risk analysis (engineering)
New hepatitis C virus (HCV) treatments deliver higher cure rates with fewer contraindications, increasing demand for treatment and healthcare costs. The cost-effectiveness of new treatments is unknown.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom